| アブストラクト | BACKGROUND: Fluoroquinolones (FQ) are broad-spectrum antibiotics effective against various infections. However, their use has been progressively restricted by guidelines due to safety concerns, leading to repeated reassessments of their indication. Despite a marked decline in prescriptions, misuse remains a concern. This study aimed to assess FQ prescribing indications in general practice in France and analyse their evolution between 2014 and 2023 in light of changing guidelines. METHODS: We conducted a descriptive observational study using data from the THIN(R) (The Health Improvement Network) database, managed by CEGEDIM-GERS DATA. This European database collects anonymized electronic health records from private practitioners in seven countries, including France since 2014. In 2023, the French panel included over 3 million patients and approximately 2000 general practitioners (GPs). Available data include administrative and medical information. Oral FQ prescriptions for patients aged>/=20years were analyzed in 2014, 2019 and 2023 for compliance with five frameworks: marketing authorization (MA), SPILF 2015 (French Infectious Diseases Society), HAS 2016 (French National Authority of Health) and EMA 2018/2019 (European Medicines Agency). Results were stratified by sex, age, molecule and indication category. RESULTS: FQ prescriptions by GPs declines by 59% between 2014 and 2023. Compliance varied by reference: approximately 75% according to MA and SPILF versus less than 25% with more recent guidelines (HAS 2016 and EMA 2018/2019). Compliance was lower in women and patients aged>/=75years. In 2023, the largest misuse was observed for urinary and prostate infections (from approximately 94% to 24%) due to changes affecting uncomplicated urinary tract infections in women. For respiratory or ear nose and throat (ENT) infections, compliance remained low (20-40%) across all references. CONCLUSIONS: Despite decreasing FQ use in general practice, many prescriptions remain non-compliant with updated recommendations, highlighting a persistent gap between clinical practices and evolving guidelines. |
|---|
| ジャーナル名 | Therapie |
|---|
| Pubmed追加日 | 2026/5/23 |
|---|
| 投稿者 | Dilange, Lisa; Hider-Mlynarz, Karima; Saade, Daniele; Jabagi, Marie-Joelle; Bertrand, Marion; Zureik, Mahmoud |
|---|
| 組織名 | EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French;National Agency for Medicines and Health Products Safety (ANSM) and French;National Health Insurance (CNAM), 93285 Saint-Denis, France.;National Health Insurance (CNAM), 93285 Saint-Denis, France. Electronic address:;karima.hider-mlynarz@ansm.sante.fr.;National Health Insurance (CNAM), 93285 Saint-Denis, France; Paris-Saclay;University, INSERM U1018, CESP Anti-Infective Evasion and Pharmacoepidemiology;Team, 75000 Paris, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42173712/ |
|---|
